EEG-based Neurofeedback to Improve Emotion Regulation in Major Depressive Disorder: A Randomized Clinical Trial
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Major Depression With Comorbid Anxiety Symptoms, Major Depressive Disorder (MDD)
In brief
The goal of this clinical trial is to evaluate whether EEG-based neurofeedback targeting the emotion regulation network through swLORETA can improve emotional regulation and reduce symptoms in adults with Major Depressive Disorder (MDD) who have not responded sufficiently to first-line treatments. The main questions it aims to answer are: * Does EEG-neurofeedback improve emotional self-regulation and reduce clinical symptoms in patients with MDD with or without anxiety symptoms? * Are changes in EEG resting-state activity and stress biomarkers (e.g., cortisol) associated with clinical improvement? Researchers will compare an active neurofeedback group, a sham (placebo) neurofeedback group, and a treatment-as-usual control group to see if real-time EEG-neurofeedback leads to greater improvement in mood, emotional regulation, and neurophysiological indicators than placebo or no additional intervention. Participants will: * Receive 10 sessions of either real or sham EEG-neurofeedback (or no sessions in the control group) over 5 weeks. * Complete clinical, psychological, and neurophysiological assessments before (week 0) and after the intervention (week 6). * Provide repeated saliva samples to assess stress-related biomarkers at week 0 and week 6. * Continue their standard pharmacological treatment throughout the study.
Key facts
- Study ID
- NCT07041073
- Run by
- Corporacion Parc Tauli
- People needed
- 72
- Starts
- 2025-05-19
- Expected to finish
- 2026-09-01
- Last updated by the study team
- 2025-06-27
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A primary diagnosis of Major Depressive Disorder (MDD), established by qualified psychiatrists according to DSM-5 criteria.
- Patients with comorbid anxiety or anxiety symptoms will be included, provided that MDD is the primary diagnosis.
- Participants must score at least 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS), indicating a moderate level of depression.
- All participants must be on a stable psychopharmacological treatment for at least 6 weeks before beginning of the study.
You may not qualify if…
- Patients with a concurrent diagnosis of MDD and other severe psychiatric disorders.
- Patients with serious physical illnesses that could interfere with study participation or the interpretation of results.
- Participants currently undergoing structured psychotherapy or other interventions unrelated to standard psychopharmacological treatment.
- Patients presenting with active suicidal ideation, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), at the time of screening will not be eligible due to associated risks.
- Active substance abuse or dependence (except nicotine).
- Intellectual disability or conditions that interfere with the ability to provide informed consent and complete the intervention (e.g., severe visual or hearing impairments).
- Pregnancy.
Where it is running
- Corporació Sanitària Parc Taulí de Sabadell — Sabadell, Barcelona, Cataluña, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.